23.03.24 () 09:14

Dailypharm

X
"پ ...鿪׾ ⼺ "
뺴ö 2018-10-22 06:30:00
/home/dailypharm/issueData2017/
"پ ...鿪׾ ⼺ "
뺴ö 2018-10-22 06:30:00
÷ ãƼ[15] ڸ̿




 
"ۿ ּȭϰ, ɹĮǾǰ 鿪׾ ߷ ޴ ȯڵ鿡 ο Ǿ ٹ ϰ ͽϴ."

(47) ڸ̿ ϴ ü 鿪׾ ž ATB-301 ϼ ȣƮ(host) 鿪ýۿ ׼ TGF- ܹ ü 鿪ý ȭ ϼ Ȱ ϴ ġ.

ȯ ⺻ TGF-⸦ ϴ ִ. Ư , , ,  ȿ Ÿ ִ ӻ Ȯεǰ ִ.

ATB-301 ٽ TGF-Ⱑ ֱ ް ִ 鿪(Immune check point inhibitor) ๰׼ ٽ ǥʿ Immune check point inhibitor ȿ ų ִ key factor Ȯεǰ ִٴ ̴.

IL-2 ü 鿪 ׾ ۿ ϴ 'â' ϰ, Ʈ󺣴 TGF-⸦ Ͽ ϼ '' ȭ Ű ҷ ۿ ִ.

"ATB-301 TGF- Ʈ󺣴 鿪׾ IL-2 in-vitroin-vivo ȿ ̸ ϰ ֽϴ. Ϸ 1б⿡ ؿ GLP ȿ½ ȹԴϴ. 2019 ӻ 1 IIa Ϸ 2022 ̼ ƿ ǥ ϰ ֽϴ."

ATB-301 ฮ Ʈ󺣴 ϼ TGF- ϼ ȭ IL-2 T cell ϼ ݷ ȭ ٸ ۿ ๰ ׾ϱ ȭŲ. Ʈ󺣴 ü ӻ Ư ۿ Ƿ ۿ ׾ȿ شȭ ִ.

"ATB-301 Ʈ󺣴 IL-2 , ̹ 㰡 鿪׾ PD-1PD-L1 CTLA-4 Ȯ մϴ. ̿ ٸ 鿪׾ Ȯ ϸ ̴ ۿ뿡 ׾ȿ ų ˴ϴ."

IL-2 ϼ ϴ ȿ ƴϱ⿡ IL-2 Ȱȭ PBMC(peripheral blood mono-nuclear cell) ϸ ü IL-2 Ȱȭ ϼ ִ T شϴ ִ. in-vitro ϸ Ʈ󺣴 ܵ IL-2 Ȱȭ PBMC ܵ ϼ ȿ Ͱ Ͽ Ʈ󺣴 IL-2 뿡 ϼ ȿ Ǵ Ȯߴ.

Ϲϴ.

- »׿ Ź帳ϴ.

=ȭ п 縦 ġ ̱ SUNY Buffalo(ָб Buffalo ķ۽) Roswell Park Cancer Institute ȭС ڻ ߽ϴ.

忡 ִ Memorial Sloan-Kettering Cancer Center(MSKCC) 鿪׾ о߿ ڻ ׾ҽϴ.

ѱ ͼ ߿ ȸ JWũ ҿ ġ (׾, ڰ鿪ġ ), ؽſ DNA vaccine(ڱð() ġ) ܹ Ǿǰ ӻ ȹ  ֽϴ.

-ڸ̿  ֳ.

= ī ۷ι ۷ι ϰ, 2017 С索 ATB-101, ׾ ATB-301, ATB-301 鿪׾ TIPS å ϰ ֽϴ. 2018 9 Ҹ DZ ϸ鼭 ATB-301 Բ ü 鿪׾ ϰ ֽϴ.

-ڸ̿ ȭ ߰ ȭ Դϱ.

=ڸ̿ ȭ dzϰ, ϸ ȭ 㰡/డ žళ ޺κ ๰ ȸԴϴ. ž ȭ ɼ ǹմϴ. κ ̼ ü /ؿ 㰡áడ ȭ /ȭ ֽϴ.

-/索 ž ATB-101 Ȳ , Ը Ź帳ϴ.

=ATB-101 , 索 ġ ž GLP 4 ȿ½Ϸ, ġῡ п ȿ Ȯ߽ϴ. ̿ Ư Ϸ Դϴ. GLP 13 ݺ Ϸ Դϴ. ӻ 2 track ̸ ӻ 13 㰡 ޴ ȹ ְ(2019 ݱ IND ), ̱ ž 2󿡼 ٷ ̰ ĺʹ ڸ̿ (2019 ݱ ̱ IND ⡤ ǥ)Դϴ.

2022 Ϲݱ⿡ 㰡 Ϸᰡ ˴ϴ, 2023 ݱ డ Ϸ ǥ ֽϴ. Ը 索 70% , ATB-101 о 索 强 Ͽ 2023 ATB-101 ߸ 2~3 ̳ ۷ι 15000 ֽϴ.

-ATB-101 ֿ, ȯ, ٽ Դϱ.

=ATB-101 С索 ġ ġ а 索 ÿ ִ ȯڸ 1 ȿ ƴ϶ 鿡 ۿ ֽϴ. 1 о, 索 ̴ 3 ȿ ๰ 뿡 compliance ȿ ƴ϶ а ۿ뵵 ֽϴ.

-ATB-101 GLP ȿ½ ϱ.

=ġ ܵ ġ 索ġ ġᱺ ȿ ȿ Ȯϰ Դϴ.

  ATB-301 ĵ

-鿪׾ ž ATB-301 Ȳ , Ը Ź帳ϴ.

=ATB-301 TGF- Ʈ󺣴 鿪׾ IL-2 in-vitro/in-vivo ȿ ̸ ϰ ֽϴ. Ϸ 1б⿡ ؿ GLP ȿ½ ȹԴϴ. 2019 ӻ 1 IIa Ϸ 2022 ̼ ƿ ǥ ϰ ֽϴ.

۷ι ׾Ϻо Ը 2016 $113B 2021 $177B ˴ϴ. ۷ι ׾ ׾ġ , 缱ġ, ġ, а Ҿ 鿪ġᰡ ׾ġ ǥؿ ڸ Ǿǰ ߰ ̿ Ծ Ը Ŀ ֽϴ.

߿ Ʈ󺣴 Ÿ ϰ ҽų 2026 8, 2023 22 ˴ϴ.

-ATB-301 ȯ, ٽ Դϱ.

=ֿ δ ϼ host 鿪ýۿ ׼ TGF- ܹ , ü 鿪ý ׾ۿ ϰ ݴϴ. ȯ ⺻ TGF-⸦ ϴ , Ư , , ,  ȿ ǰ ֽϴ.

ٽ δ TGF-Ⱑ ֱ ް ִ 鿪(Immune check point inhibitor) ๰׼ ٽ ǥʿ Immune check point inhibitor ȿ ų ִ key factor ϴ. IL-2 ü 鿪 ׾ ۿ ϴ 'â' ϰ, Ʈ󺣴 TGF-⸦ Ͽ ϼ '' ȭ Ű ҷ ۿ ֽϴ.

-ATB-301 ฮ ġ ٰŴ Դϱ.

=ฮ Ʈ󺣴 ϼ TGF- ϼ ȭ IL-2 T cell ϼ ݷ ȭ ٸ ۿ ๰ ׾ϱ ȭŰ, Ʈ󺣴 ü ӻ Ư ۿ Ƿ ۿ ׾ȿ Ű Դϴ.

  Ʈ󺣴 IL-2 in-vitro

-ATB-301 Ȯ强 Ź帳ϴ.

=ATB-301 Ʈ󺣴 IL-2 , ̹ 㰡 鿪׾ PD-1/PD-L1 CTLA-4 Ȯ մϴ. ̿ ٸ 鿪׾ Ȯ ϸ ̴ ۿ뿡 ׾ȿ ų ˴ϴ.

-ATB-301 Ʈ󺣴 IL-2 in-VITRO ࿬ ¿.

=IL-2 ϼ ϴ ȿ ƴϱ⿡ IL-2 Ȱȭ PBMC(peripheral blood mono-nuclear cell) ϸ ü IL-2 Ȱȭ ϼ ִ T شϴ ֽϴ. in-vitro ϸ Ʈ󺣴 ܵ IL-2 Ȱȭ PBMC ܵ ϼ ȿ Ͱ Ͽ Ʈ󺣴 IL-2 뿡 ϼ ȿ Ǵ Ȯ߽ϴ.

- ȹ Դϱ?

= ڸ̿ ׾ ATB-301 Ʈ󺣴 ְ ǰ ٸ ׾ ڸ̿ ȸ 'Global Leader of Cancer Treatment' ǵ ּ ϰڽϴ. ׾ ġ  ׾ ġ ϸ ޴ ȯڵ鿡 ִ Դϴ.
뺴ö (sasiman@dailypharm.com) ٸ
  • μ
  • īī
  • ̽
  • Ʈ
  • 0
ñ
ǰ
0
͸ǰ | Ǹǰ߾ Ģ
ݱ

Ǹ ͸ , Ǹ ̸ ̵ ˴ϴ. ͸ ʸ ϸ, ͸ մϴ.

ڹ(-ڴϾ-ʱ ) ˵ ϸ ȸ Խ ⡯ ĺ Ʈ ׻ ֻܿ ˴ϴ. ο ø Ϲȸ Խ ĺ ڴϾ ȸ ϴܿ ǽð ˴ϴ.

뺸 ϰ ̵ ̿ Ǵ ֽϴ.

  • ۱ǡΰݱ Ÿ Ǹ ħϴ

    α׷ ϰ , ȳϴ Խù

    Ÿ Ǵ 3 ۱ Ÿ Ǹ ħ Խù

  • ٰ 桤 Ѽϴ Խù

    Ư ̿ ο ν 弳

    Ư 븳 ϴ

    Ȯ ȵ ҹ Ű

    弳 , Ӿ

    Ź, ɿ ˵Ǵ ( û )

    Ư ̳ ü ϴ

    Ư ѼϿ ش ûϴ

    Ư (ֹεϹȣ, ȭ, ּ ) Խϴ

    Ÿ ID Ȥ г ϴ

  • Խ Ư ѵǴ

    ʴ

    翡 ߺ

    κ Ͽ ݺ ϴ 쵵

    Խù,

    Ե Խù

    Խù б

  • û ִ

  • Ÿ

    ʿ伺 ̸

    Ÿ ˵Ǵ 縦

    Ÿ  ڰ ʿϴٰ ǴܵǴ

  • Ȯ

    ۱ڷκ , , ϴ

    Ÿ ʻ ħϰų ϴ

    翡 ̿ (Ÿ ID, йȣ )

  • ̻ Ϻ ׿ ̿ 縦 , Ρ ó ֽϴ.

    õ ̴ ҹ Ǵܵǰų ϸ 񽺿 ٶ ʴٰ ǴܵǴ ġ ϰڽϴ.

    رŸ ϸ ڿ ֽʽÿ. ּҴ dailypharm@dailypharm.comԴϴ.

ֽż ݴ
ٺ Ϲݾ ǸŰ (2023 03)
λ-泲 ౹ 71
ǰ ְ
ڶ(20) 6,000 5,500 500 5,967
ѽŻ÷(10) 3,500 2,000 1,500 2,709
޾(100) 24,000 22,000 2,000 22,833
Ʒγΰ(100) 30,000 24,000 6,000 26,917
īɾ(10g) 8,000 5,100 2,900 6,248
Ľõ򿬰(5g) 5,000 4,000 1,000 4,510
Ź(4) 5,000 3,400 1,600 4,008
λ絹÷(100) 37,000 30,000 7,000 31,961
̰źĸ(100) 35,000 29,000 6,000 31,905
(10) 6,000 4,000 2,000 4,777
Ժ(10) 4,000 3,000 1,000 3,427
ڱ׸(20) 5,000 4,000 1,000 4,225
ť(10) 3,500 2,200 1,300 2,774
Ȱť(1) 1,000 800 200 974
Ǯɾ(3.3ml) 25,000 22,000 3,000 24,200
޵𿬰(10g) 7,000 5,000 2,000 6,103
öŸ(34) 13,000 9,800 3,200 11,176
뽺ī(20g) 22,000 18,000 4,000 19,655
ġ(1) 1,000 800 200 999
ӽ÷(21) 10,000 7,000 3,000 8,676
ͺ(10) 3,500 2,000 1,500 2,947
ݿ(1ڽ) 3,000 2,200 800 2,687
׶÷糪ƮŸ(6) 8,000 6,000 2,000 7,090
߽Ÿ(120) 70,000 40,000 30,000 52,842
Źĸ(10ĸ) 3,000 2,000 1,000 2,911
Ÿ̾(120) 60,000 40,000 20,000 49,565
տ(60ĸ) 28,000 24,000 4,000 26,276
Ÿ̷ER(6) 3,500 2,000 1,500 2,613
ٿ(30g) 12,000 8,000 4,000 10,086
(120) 25,000 18,000 7,000 21,836
Ʒ(6) 4,000 3,000 1,000 3,271
ǽõĸ(270ĸ) 110,000 80,000 30,000 95,000
B(120) 70,000 60,000 10,000 64,368
׳(10) 3,000 2,000 1,000 2,450
6̺(10) 3,000 2,000 1,000 2,929
(60) 230,000 200,000 30,000 202,941
Ⱦ 12,000 9,000 3,000 10,449
ü



ͳݽŹϹȣ: 00048 | 2005.09.09 | : | : ȣ | ּ: ı 128 SK V1 GL ƮνƼ A 401ȣ
ȭ : 02-3473-0833 |ѽ : 02-3474-0169 | ûҳ⺸ȣå(å ű)
Contact dailypharm@dailypharm.com for more information
ϸ () ϴ ۱ǹ ˵Ǹ, 縦 ֽϴ.